Vinorelbine: An update and review of activity

Clinical Oncology

Volumn 8, Issue 6, 1996, Pages 353-357

  Johnson, S A N ^a  

^a TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NAVELBINE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; DRUG EFFICACY; DRUG METABOLISM; DRUG RESISTANCE; HUMAN; LUNG CANCER; PRIORITY JOURNAL; REMISSION; REVIEW;

EID: 0030431435     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(96)80075-6     Document Type: Review

References (60)

1. Johnson IS, Wright IF, Svoboda GH, et al. Antitumor principles derived from Vinca rosea linn: I. Vincaleukoblastine and leurosine. Cancer Res 1960;20:1016-22.
2. Mangeney P, Andriamialisoa RZ, Lallemand J-Y, et al. 5′-Nor-anhydrovinblastine. Prototype of a new class of vinblastine derivatives. Tetrahedron 1979;35:2175-9.
3. Jordan MA, Himes RH, Wilson L. Comparison of the effects of vinblastine, vincristine and vindesine on microtubule dynamics and cell proliferation in vitro. Cancer Res 1985;45:2741-7.
4. Binet S, Chaineau E, Fellows A, et al. Immunofluorescence study of the action of Navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer 1990;46:262-6.
5. ®. Semin Oncol 1989;16(suppl 4):15-20.
6. ® in a human non-small cell lung cancer line. Proc AACR 1995;36:A3637.
7. Maral N, Bourut C, Chenu E, et al. Experimental antitumour activity of 5′-nor-anhydrovinblastine (Navelbine). Cancer Lett 1984;22:49-54.
8. Tsuruo T, Inaba M, Tashiro T, et al. Evaluation of antitumour activity of Navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice. Anticancer Drugs 1993;5:634-40.
9. Ashizawa T, Asada M, Kobayashi E, et al. Combination effect of Navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukaemia and human lung carcinoma xenografts in mice. Anticancer Drugs 1993;4:577-83.
10. ®) Invest New Drugs 1995;13:13-21.
11. Maral R, Bourut C, Chenu E, et al. Experimental in vivo cross resistance of vinca alkaloid drugs. Cancer Chemother Pharmacol 1981;5:197-9.
12. Marquet P, la Chatre G, Debord L, et al. Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 1992;42:545-7.
13. Rahmani-Jourdheuil D, Coloma F, Placidi M, et al. Human hepatic uptake of two vinca alkaloids: Navelbine and vincristine. J Pharm Sci 1994;83:468-71.
14. Rowinsky EK, Noe DA, Trump DL, et al. Pharmacokinetic, bioavailability and feasibility study of vinorelbine in patients with solid tumours. J Clin Oncol 1994;12:1754-63.
15. Variol P, Puozzo C, Chevallier B, et al. Pharmacokinetics of oral vinorelbine in women with advanced breast cancer. Proc AACR 1996;37:A1229.
16. Mathe G, Reizenstein P. Phase I pharmacologic study of a new Vinca-alkaloid: Navelbine. Cancer Lett 1985;27:285-93.
17. Khayat D, Covelli A, Variol P, et al. Phase I and pharmacologic study of intravenous vinorelbine in patients with solid tumour. Proc ASCO 1995;14:A1518.
18. ® in advanced breast cancer. Semin Oncol 1989;16(supp 4):33-6.
19. Fumoleau P, Delgado FM, Delozier T, et al. Phase III trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-52.
20. Garcia-Conde J, Lluch A, Martin M, et al. Phase II trial of weekly iv vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994;5:854-7.
21. Romero A, Rabinovich MG, Vallejo CT, et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994;12:336-41.
22. Weber BL, Vogel C, Jones S, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995;13:2722-30.
23. Bruno S, Puerto VL, Mickiewicz E, et al. Phase II trial of weekly iv vinorelbine as a single-agent in first-line advanced breast cancer chemotherapy: The Latin-American experience. Am J Clin Oncol 1995;18:392-6.
24. Twelves CJ, Dobbs NA, Curnow A, et al. A Phase II multicentre UK study of vinorelbine in advanced breast cancer. Br J Cancer 1994;70:990-3.
25. Gasparini G, Caffo O, Barni S, et al. Vinorelbine is an antiproliferative agent in pre-treated advanced breast cancer patients: A Phase II study. J Clin Oncol 1994;12:2094-101.
26. Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994;5:423-6.
27. Speilmann N, Dorval T, Turpin F, et al. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 1994;12:1764-70.
28. ® and doxorubicin as first-line chemotherapy of metastatic breast cancer. Proc ASCO 1994;13:A203.
29. Costa MA, Cabral-Filho S, Correa M, et al. Phase II study of sequential Navelbine and doxorubicin for the treatment of metastatic breast cancer: Preliminary results. Proc ASCO 1996;15:A65.
30. Terzoli E, Nistico C, Ranuzzi M, et al. Weekly epirubicin and vinorelbine in advanced breast cancer: Preliminary results. Proc ASCO 1995;14:A180.
31. Llombard-Cussac A, Spielman M, De Balincourt C, et al. Vinorelbine/mitozantrone as first-line combination for metastatic breast cancer resistant to anthracycline adjuvant regimen. Proceedings of the Fifth International Congress on Anticancer Chemotherapy. 1995;156(abstract O679).
32. Dieras V, Pierga JY, Extra JM, et al. Results of a combination of Navelbine and fluorouracil in advanced breast cancer with a group sequential design. Proceedings of the European Society of Medical Oncology 1992. Ann Oncol 1992;31(suppl 4): 46(A178).
33. Scheithauer W, Kornek G, Haider K, et al. Effective second-line chemotherapy of advanced breast cancer with Navelbine and Mitomycin-C. Breast Cancer Res Treat 1993;26:49-53.
34. Dabaja BS, Shamsedding AI, Salem ZMK, et al. Treatment of metastatic breast cancer with vinorelbine and cisplatin: A clinical Phase II trial. Proceedings of the Fifth International Congress on Anticancer Chemotherapy 1995;241 (abstract P444).
35. Iaffaioli RN, Tortoriello A, Facchini G, et al. A Phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer. Br J Cancer 1995;72:1256-8.
36. Fabi A, Jonachella R, Savarese A, et al. A Phase II trial of vinorelbine as first-line chemotherapy for metastatic breast cancer. Proc ASCO 1995;14:A187.
37. Leone B, Vallejo C, Romero A. Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. Proc ASCO 1995;14:A187.
38. Ibraham NK, Hortobagyi GN, Valero V, et al. Phase I study of vinorelbine and paclitaxel by simultaneous 3 hour infusion with G-CSF support for untreated metastatic breast cancer. Breast Cancer Res Treat 1996;37(suppl):A107.
39. Fumoleau P, Delecroix V, Gentin M, et al. Docetaxel in combination with vinorelbine as first-line CT in patients with MBC: Phase I dose-finding study. Proceedings of 8th ECCO. Eur J Cancer 1995;31A(suppl 5):A938.
40. Van Praagh I, Leduc B, Feillel V, et al. Neoadjuvant NEM chemotherapy regimen for operable breast cancer: Results of a co-operative study on 69 patients. Proc ASCO 1995; 14:A242.
41. Furuse K, Niitani H, Wakui A. Phase I study of vinorelbine (Navelbine) by single or intermittent administration. Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy 1989. Invest New Drugs 1989;7:456.
42. Furuse K, Kubota K, Kawahara M, et al. A Phase II study of vinorelbine, a new derivative of vinca-alkaloid, for previously untreated advanced non-small cell lung cancer. Lung Cancer 1994;11:385-91.
43. Depierre A, Lemarie E, Dabouis G, et al. A Phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991;14:115-9.
44. O'Rourke M, Crawford J, Schiler J, et al. Survival advantage for patients with stage IV NSCLC treated with single-agent Navelbine in a randomized controlled trial. Proc ASCO 1993;12:A1148.
45. Depierre A, Chastang C, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial. Ann Oncol 1994;12:360-7.
46. le Chevalier T, Brisgand D, Douillard J-Y, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7.
47. Smith TJ, Hillner BE, Neighbors D, et al. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin for non-small cell lung cancer. J Clin Oncol 1995;13:2166-73.
48. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomised Phase III trial of cisplatin vs CDDP plus Navelbine in treatment of advanced non-small cell lung cancer: Report of a Southwest Oncology Group Study (SWOG - 9308). Proc ASCO 1996;15:A1110.
49. Santomaggio C, Righi R, Tucci E, et al. Carboplatin and vinorelbine in the treatment of patients affected by advanced non-small cell lung cancer. Proc ASCO 1994;13:A1211.
50. Morere JF, Brunet A, Duran A, et al. Ifosfamide and vinorelbine in advanced non-small cell lung cancer. Proc ASCO 1994;13:A1149.
51. Gralla JR, Kardinal CG, Clark RA, et al. Enhancing the safety efficacy and dose intensity of vinorelbine combination chemotherapy regimens. Proc ASCO 1993;12:A1122.
52. Vialle J, Rousseau P, Souhami L, et al. A completed Phase I/ II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated thoracic irradiation in inoperable NSCLC. Proc 8th ECCO. Eur J Cancer 1995;31A(suppl 5):A1083.
53. George MJ, Heron JF, Kerbrat P, et al. Navelbine in advanced ovarian epithelial cancer: A study of the French Oncology Centre. Semin Oncol 1989;16(suppl 4):30-2.
54. Conroy T, Etienne PL, Adenis A, et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J Clin Oncol 1996;14:164-70.
55. Gebbia V, Mantovani G, Agostara B, et al. Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin and 5-fluorouracil: A multicenter Phase II trial. Ann Oncol 1995;6:987-91.
56. ®) in previously treated Hodgkin's disease and non-Hodgkin's lymphomas. In: Solal-Celigny P, editor. Navelbine (vinorelbine): Up-date and new trends. Libby Eurotext, Paris, London, 1991: 261-4.
57. Devizzi L, Santoro A, Bonfante V, et al. Vinorelbine: An active drug for the management of patients with heavily pre-treated Hodgkin's disease. Ann Oncol 1994;5:817-20.
58. Bruno S, Savignano R, Corrado G, et al. Vinorelbine: A new vinca-alkaloid active in refractory/relapsed lymphomas. A Phase II study. Proc ASCO 1994;13:A1300.
59. Rule S, Tighe M, Johnson S. Vinorelbine (Navelbine) an active agent in the salvage of heavily pre-treated patients with Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol 1996;93(suppl 2):A1402.
60. Ferme C, Bastion Y, Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 1995;6:453-9.